A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199)

Merck Sharp & Dohme LLC1,523 enrolled

Overview

The purpose of this study is to collect information of the risk profile of patients with type 2 diabetes mellitus, their treatment concerning meeting the guidelines for treatment of diabetic patients type 2 published by the Deutsche Diabetes Gesellschaft (DDG) on October 13, 2008

Study Type

OBSERVATIONAL

Enrollment

1,523

Conditions

Type 2 Diabetes Mellitus

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- Newly diagnosed with Type 2 diabetes in whom treatment with metformin in the individual maximal tolerated dose (at least four weeks on stable dose) resulted in HbA1c \>6.5% \- No contraindication or intolerability to metformin Exclusion Criteria: \- Currently being administered a combination therapy for the treatment of their Type 2 diabetes

Outcomes

Primary Outcomes

Change From Baseline for Mean Hemoglobin A1c (HbA1C)

Change from baseline was defined as mean HbA1c baseline value minus the mean HbA1c end of observation value.

Time frame: Baseline and end of Observation (up to Month 6)

Change From Baseline for Mean Fasting Blood Glucose (FBG)

Change from baseline was defined as mean FBG baseline value minus mean FBG end of observation value.

Time frame: Baseline and end of Observation (up to Month 6)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.